***R. ALTA CHARO***

***Knowles Professor Emerita of Law & Bioethics***

***University of Wisconsin- Madison***

510 N St SW, #N-227 Washington DC 20024

racharo@wisc.edu cell: 608-2394917

**EDUCATION AND BAR ADMISSION**

1979 - 1982 J.D. (Stone Scholar), Columbia University School of Law

Articles Editor, Columbia Journal of Environmental Law

1975 - 1979 A.B. (cum laude, biology), Harvard University

1982 Admitted to the Bar of the State of New York

**ACADEMIC APPOINTMENTS**

09/89 – present Ass’t Prof (’89-’95), Assoc Prof (’95-’98), Prof (’98-’03), Elisabeth S. Wilson Professor (’03-’05); *Warren P. Knowles Professor* (’05 to ’20, **emerita ’21 – present**) UW Law School

09/89 – 06/17 Ass’t Prof (’89-95), Assoc Prof (’95-’98), Prof (’98-’17), Dept of Medical History and Bioethics, UW School of Medicine & Public Health

08/11 – 08/12 Associate Dean for Academic Affairs, UW Law School

01/06 – 12/06 Visiting Professor of Law, UC – Berkeley Law School

07/02 – 01/06 Associate Dean for Research and Faculty Development, UW Law School

09/85 - 06/86 Fulbright Lecturer in Law at Université de Paris 1 (Panthéon-Sorbonne)

06/83 – 05/85 Lecturer, Columbia University School of Law

06/82 – 05/85 Associate Director (1982-1985) Legislative Drafting Research Fund (Columbia U.)

**GOVERNMENT APPOINTMENTS**

05/12 – 01/15 Member, Advisory Council, NIH Nat’l Ctr for the Advancement of Translational Sciences

07/09 – 06/11 Senior Policy Advisor, Office of the Commissioner, US Food & Drug Administration

11/08 – 01/09 Member, Obama-Biden Transition Team (HHS Review)

09/88 – 07/89 Policy Analyst, Population Policy Division, US Agency for International Development

08/86 – 08/88 Legal Analyst, Biological Applications Prog., US Congress’ Office of Tech. Assessment

**ELECTED MEMBERSHIPS**

Elected Member, German Academy of Sciences (Leopoldina) (2022)

Elected Fellow, American Association for the Advancement of Science (2020)

Elected Member, American Academy of Arts & Sciences (2020)

Elected Member, National Academies’ Institute of Medicine (2006) (now “National Acad. of Medicine”)

Elected Member, Wisconsin Academy of Sciences, Arts and Letters (2005)

Elected Fellow, World Technology Network (2004)

Elected Fellow, Inst. of Society, Ethics & Life Sciences (Hastings Center) (1993)

**COURSES TAUGHT**

Food & Drug Law; Biotechnology Law; Bioethics; Medical Ethics; Public Health Law; Reproductive Rights Law; Statutory Drafting; Stem Cell and Cloning Research Policy; Torts

**WORKING LANGUAGES**: English; French (advanced intermediate); Spanish (basic); Italian (some reading)

**SHORT-TERM VISITING LECTURESHIPS AND PROFESSORSHIPS**

Duke University Fuqua School of Business (upcoming spring 2025)

University of Virginia Law School (Charlottesville, Virginia), January to April 2004

Facultad Latinoamericana de Ciencias Sociales (Buenos Aires, Argentina), November 2003

Nova Law School (Ft. Lauderdale, Florida), March 2001

Instituto Superior de la Medicina (Santiago, Cuba), November 1996

Escuela Latinoamericana de la Bioetica (La Plata, Argentina), October 1992

Centre de Droit de la Famille, Université de Lyon (Lyon, France), June 1992

Fachbereich Rechtswissenschaft, Justus-Liebig-University (Giessen, Germany), May 1992

**NATIONAL COMMISSIONS**

1996 - 2001 Member, U.S. National Bioethics Advisory Commission (President Clinton)

1993 - 1994 Member, National Institutes of Health Human Embryo Research Panel

1990 Member, Life & the Law Consultative Comm., Canadian Law Reform Comm.

**AWARDS, HONORS, GRANTS AND FELLOWSHIPS**

2021 Inaugural David A. Hamburg Distinguished Fellow, Nuclear Threat Initiative (biological threats program)

2019 - 2020 Berggruen Fellow, Stanford Univ. Ctr for Advanced Study of Behavioral Sciences

2014 UW Chancellor’s Distinguished Teaching Award

2013 Adam Yarmolinsky Medal by the Institute of Medicine (now Nat’l Acad. of Med.)

2007 Greenwall Grant, “Legislative Approaches to Conscience Clauses”

1998 H.I. Romnes award (UW-Madison)

1998 Senior Fellow, Stanford Center for Biomedical Ethics, Stanford University

1996 Fellow, Green Center for the Study of Science and Society, UT – Dallas

1988 – 1989 AAAS Diplomacy Fellow (detailed to U.S. Agency for International Development)

1985 - 1986 Professeur Associé/Fulbright Lecturer, Université de Paris I (Panthéon-Sorbonne)

**TESTIMONY**

U.S. Congress (Senate):

The Implications of Reversing Roe v. Wade (2005)

Protecting the Interests of Women in Cloning Research (2003)

Ethics and Regulation of Somatic Cell Nuclear Transfer Research (2002)

U.S. Congress (House):

Off-Label Drug Marketing (2017)

Ethics of Fetal Tissue Research (2016)

Ethics of Cloning Human Beings (1997)

HHS Ethics Advisory Board on Fetal Tissue Research (2020)

President’s Comm. on Gulf War Veterans' Illnesses, Ethics of Experimenting on Military Personnel (1996)

Wisconsin State Legislature (Assembly and Senate):

Criminalizing Cloning Research (2005)

Professionalism and Conscience Clauses (2005)

Parental Consent for Abortion (1995)

Pregnancy and Drug Addiction (1993)

Introducing RU-486 (1993)

California State Legislature (Senate), Ethics Standards for Human Embryonic Stem Cell Research (2005)

N.J. Bioethics Commission, Surrogate Motherhood (1988)

National Academy of Sciences/Institute of Medicine

Federal Regulation of Stem Cell Research (2004)

Options for Regulating Reproductive Cloning (2001)

Expert for Planned Parenthood of Western Washington in *Stormans vs Selecky* (Case No. C07-5374-RBL, U.S. District Court for the Western District of Washington (2008- 2010). In court testimony (2011).

**CONSULTANCIES**

Consultant on in vitro and tissue donation research ethics, Bexord (2025 – present)

Consultant on clinical trial design and post trial responsibilities, CSL (2024 – present)

Consultnt on emerging technology governance, Microsoft (2024 – 2025)

Consultant on ethical issues w/ OTC drugs/devices, cosmetics, supplements, Kenvue (2023 – 2024)

Consultant on ethical issues w/embryonic stem cell and other tissue research, Fujifilm (2023 - present)

Consultant on use of fetal tissue in drugs, cosmetics, BIO (2023 – 2024)

Consultant on innovation in fertility treatment, Gameto (2022 – 2024)

Consultant on innovation in gametogenesis, Conception (2022 – present)

Consultant on xenotransplantation ethics, Egenesis (2022 – 2024)

Consultant on ethics and gene therapy trials, Vertex (2022 – 2024)

Consultant/expert witness on ethics of fetal tissue research, Planned Parenthood (2022 – present)

Consultant on conservation/de-extinction genome editing, Colossal (2021 – present)

Consultant on safety/security/social responsibility, BioMADE (2020 – 2022)

Consultant on research trial design, Johnson & Johnson (2012 – 2013; 2016 - present)

Consultant on fertility clinic management, University of Utah (2014)

Consultant on research trial design, Cleveland BioLabs (2012)

Consultant on research trial design, Stem Cells, Inc. (2006)

Consultant on research funding standards, California Institute for Regenerative Medicine (2005)

Macy Foundation, Designing a Genetics Curriculum for Medical Schools (1998)

National Academies, Institute of Medicine:

(1) Using Commissions to Develop Bioethics Policy (1993)

(2) Constitutionality of Excluding Women from Research (1993)

(3) Assessing Genetic Risk (1992)

(4) Including Women in Research Trials (1991)

(5) Biomedical Politics (1990)

(6) Adoptees' Rights to Obtain Genetic Information (1989)

U.S. Congress, Office of Technology Assessment:

(1) Population Screening for Cystic Fibrosis (1991-1992)

(2) Genetic Testing in the Workplace (1990)

U.S. Agency for International Development, Office of Population:

(1) Legal Obstacles to Family Planning in Ghana (1990)

(2) Evaluation of the OPTIONS Population Policy Project (1989)

(3) OPTIONS Project Law Analyst - Chad, Mali, Ivory Coast (1988)

Commission on Uniform Laws, Draft Legislation on Surrogacy (1989)

N.J. Bioethics Commission, Draft Legislation on Living Wills (1988)

**PROFESSIONAL ACTIVITIES AND BOARD MEMBERSHIPS**

*(“NASEM” is National Academies of Sciences, Engineering and Medicine, formerly the NAS, NAE, IOM)*

*("DARPA" is Defense Advanced Research Projects Agency, part of the Dept of Defense)*

*("NIH" is National Institutes of Health, part of the Dept of Health and Human Services)*

*("ELSI" is Ethical, Legal and Social Issues)*

24 – present Member, NASEM Comm. on Enhancing Biotechnology Innovation and Applications for National Security

24 – present Member, NASEM Committee on Biotechnology Capabilities for National Security Needs

24 – present Member, NASEM Standing Committee on Advances and National Security Implications of Transdisciplinary Biotechnology

24 – present NASEM Committee on Artificial Intelligence and Automated Laboratories for Biotechnology: Leveraging Opportunities and Mitigating Risks--A Workshop.

23 – 24 Member, NIH Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC)

22 – 23 Member, NASEM Comm of Emerging Science, Technology and Innovation

(consensus study follow-on to standing committee)

21 – 23 Member, Organizing Committee, 3rd Int’l Summit on Human Genome Editing

(March 2023) – joint NASEM and UK Royal Academy

21 – present Member, Board of Directors, The Allen Institute

21 – present Member, Sci Adv Comm, Assoc for Responsible Research in Genome Editing (ARRIGE)

20 - present Member, NASEM Standing Comm on Emerging Infectious Diseases

20 – 21 Member, NASEM Comm on Equitable Allocation of COVID-19 Vaccines

19 – 21 Member, Expert Advisory Committee on Genome Editing, World Health Organization

18 – present Member (Co-Chair ’21 – ), NASEM Comm on Emerging Science, Technology & Innovation

18 – 21 Member, Nuclear Threat Initiative's Program on Biosecurity

18 - present Member, NASEM Comm. on Aerospace Medicine & Medicine of Extreme Environments.

18 - present Member, NASEM Science and Entertainment Exchange

17 – 18 Member, Planning Committee, International Workshop on Governance of Dual Use Research in the Life Sciences: Advancing Global Consensus on Research Oversight.

16 – present Member, Lawrence Berkeley Laboratory Biosciences Expert Advisory Committee

16 – 20 Member, DARPA (DoD) biotechnology and neuroscience ELSI advisory committees

16 – present Member, NASEM Intelligence Science and Technology Experts Group (ISTEG)

16 - present Member, Ethics Committee, Int'l Society for Stem Cell Research

16 - present Member, Policy Committee, Int'l Society for Stem Cell Research

16 - 18 Co-Founder and Co-Chair, NASEM Forum on Regenerative Medicine

16 - 17 Member, Planning Committee, Second International Summit on Genome Editing

15 – 17 Co-Chair, NASEM Human Gene Editing Study Committee

15 - 16 Member, NASEM Committee on Mitochondrial Replacement Therapy

14 – 20 Member, National Academy of Medicine (formerly IOM) Council

14 - present Member, NASEM Board on Health Sciences Policy

14 – 20 Member, NASEM Committee on Science, Technology and Law

14 - 15 Member, Board of Directors, Generations Fertility Care, Inc.

13 - 14 Member, NASEM Committee to Assess NIH Recombinant DNA Advisory Comm.

13 – 21 Member, Editorial Board, Journal of Law and the Biosciences

13 - 16 Member, NASEM Roundtable Forum on Synthetic Biology

12 - 14 Member, NASEM Committee on Responsible Science

12 - 13 Member, NIH Working Group on Use of Chimpanzees in Research

11 - 12 Member, NASEM Committee on Safety of the Pediatric Vaccine Schedule

06 - 10 Co-Chair, NASEM Human Embryonic Stem Cell Research Advisory Comm.

06 - 08 Member, Policy Board, American Foundation for AIDS Research (“amfAR”)

06 - 12 Member, NASEM Board on Population Health and Public Health Practice

06 - 09 Member, Advisory Board, Women’s Bioethics Project

06 - 09 Member, Ethics Advisory Board, International Society for Stem Cell Research

05 - 06 Member, NASEM Committee to Assess the Drug Safety System in the U.S.

05 - 09 Member, Standards. & Accountability Group, Calif. Inst. for Regenerative Medicine

04 - 06 Member, Bioethics Advisory Board, Howard Hughes Medical Institute

04 - 05 Member, NASEM Comm. on HIVNET 012 HIV Perinatal Transmission Trials

04 - 05 Member, NASEM Comm. on Embryonic Stem Cell Research Guidelines

04 - 09 Member, Advisory Board, Project on Reproductive Genetics, Johns Hopkins University

04 - 06 Member, Nat’l Medical Committee, Planned Parenthood Federation of America

04 – 20 Member, Advisory Board, Wisconsin Stem Cell Research Program

04 Member, Medical Research Policy Comm., John Kerry for President campaign

03 - 12 Member, Editorial Board, Public Library of Science-Medicine

02 - 05 Member, NASEM Comm. on Smallpox Vaccination Implementation

02 - 03 Member, NASEM Comm. on Preventing Destructive Applications of Biotechnology

02 – 20 Member, Scientific Advisory Board, WiCell

01 - 07 Member, NASEM Board on Life Sciences

00 - 01 Member, Editorial Board, American Journal of Bioethics

00 - 01 Member, Howard Hughes Medical Institute Bioethics Steering Committee

99 - 05 Member, Editorial Board, Monash Bioethics Review

99 - 00 Member, Open Society Institute Program on Reproductive Health & Rights

98 - 03 Member, Editorial Board, Cloning: Science and Policy

98 - 00 Member, Board of Directors, Society for the Advancement of Women’s Health Research

97 - 00 Member, Board of Directors, Foundation for Genetic Medicine

95 - 97 Member, Board of Directors, American Association for Bioethics

93 – 19 Member, Editorial Board, Journal of Law, Medicine and Ethics

92 - 94 Member, Board of Directors, International Projects Services Assistance

91 - 08 Member, Board of Directors, The Alan Guttmacher Institute (except 97, 01, 07)

90 - 92 Member, Board of Directors, International Association of Bioethics

90 - 93 Member, The Milazzo Group

89 - 92 Member, American Civil Liberties Union, Wisc. Chapter Lawyers' Committee

**GOVERNMENT AND NATIONAL ACADEMIES REPORTS**

National Academy of Sciences, Engineering and Medicine, “Strategic Report on Research and Development in Biotechnology for Defense Innovation” (committee member) (January 2025)

National Academy of Sciences, Engineering and Medicine, “Toward Equitable Innovation in Health and Medicine: A Framework (committee member) (August 2023)

National Academy of Sciences, Engineering and Medicine, “Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics” (committee member) (January 2021)

National Academy of Sciences, Engineering and Medicine, "Framework for Equitable Allocation of COVID-19 Vaccine” (committee member) (September 2020)

National Academy of Sciences, Engineering and Medicine, "Human Genome Editing: Science, Ethics and Governance" (February 2017) (committee co-chair)

Institute of Medicine, “Ethical and Social Policy Considerations of Novel Techniques for Prevention of Maternal Transmission of Mitochondrial DNA" (committee member) (2016)

Institute of Medicine, "Oversight and Review of Clinical Gene Transfer Protocols: Assessing the Role of the Recombinant DNA Advisory Committee" (committee member) (2013)

NIH Working Group on "Use of Chimpanzees in Research" (working group member) (2013)

Institute of Medicine, "Safety of the Pediatric Vaccine Schedule" (2013) (committee member)

National Academy of Sciences, “Final Guidelines for Human Embryonic Stem Cell Research" (committee co-chair) (2010)

National Academy of Sciences, “Revised Guidelines for Human Embryonic Stem Cell Research" (committee co-chair) (2008)

National Academy of Sciences, “Guidelines for Human Embryonic Stem Cell Research – Update #2" (committee co-chair) (2008)

National Academy of Sciences, “Guidelines for Human Embryonic Stem Cell Research – Update #1" (committee co-chair) (2007)

Institute of Medicine, "The Future of Drug Safety" (committee member) (September 2006)

California Institute for Regenerative Medicine, "Regulations for the Ethical Practice of Stem Cell Research" (member of Standards Working Group; principal drafter (with Lo & Lomax) of all regulations.

National Academy of Sciences, "Ethics Guidelines for Embryonic Stem Cell Research" (committee liaison from Board on Life Sciences and functional committee member) (April 2005)

Institute of Medicine, "Review of HIVNET 012 Trial for Prevention of Mother-to-Child Transmission of HIV" (April 2005) (committee member)

Institute of Medicine, "The Smallpox Vaccination Program: Public Health in an Age of Terrorism" (March 2005) (committee member)

Institute of Medicine, "Review of the CDC’s Smallpox Vaccination Program Implementation: Letter Report #6 (July 2004); Letter Report #5 (December 2004); Letter Report #4 (August 2003); Letter Report #3 (May 2003); Letter Report #2 (March 2003); Letter Report #1" (January 2003) (committee member)

National Bioethics Advisory Commission, "Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries" (2001) (commission member).

National Bioethics Advisory Commission, "Ethical and Policy Issues in the Oversight of Human Research in the United States" (2001) (commission member).

National Bioethics Advisory Commission, "Research Using Stored Human Biological Materials: Ethical Issues and Policy Guidance" (1999) (commission member)

National Bioethics Advisory Commission, "Ethical Issues in Human Stem Cell Research" (1999) (commission member; recused part way through report for possible appearance of conflict of interest)

National Bioethics Advisory Commission, "Research Involving Persons with Mental Disorders that May Affect Decisionmaking Capacity" (1998) (commission member)

National Bioethics Advisory Commission, "Cloning Human Beings" (1997) (commission member)

NIH Human Embryo Research Panel, "Report of the Embryo Research Panel" (1994) (panel member)

U.S. Congress, Off. of Technology Assessment, "Infertility: Medical & Social Choices" (1988) (legal analyst)

U.S. Congress, Office of Technology Assessment, "Artificial Insemination Practice in the United States" (1988) (study director).

N.Y.C. Charter Revision Commission, "Proposed Amendments to the Charter of the City of New York" (950 pp) (1983) (assistant director for research).

**PUBLICATIONS**

MacKenzie, **Charo** et al, “Consensus Statement on In Utero Gene Editing and Therapy” (in draft)

Charo, “The Sweet Smell of the Rose” in Beauvais (ed.), Promoting the ‘Human’ in Law, Policy, and Medicine (2025)

Charo, “Back to the Future in Alabama” New England Journal of Medicine (on-line March 6, 2024; in print April 4, 2024)

Barlevy, Juengst, Kahn, Moreno, Lambert, **Charo**, Chneiweiss, Farooque, Guston, Hyun, Knoepfler, Selin, Wilbanks, Zaghlula, Scott, “Governing with public engagement: an anticipatory approach to human genome editing” Science and Public Policy, 00:1-12 scae010 (25 March 2024)

Mathews, Abernethy, Chaikof, **Charo**, Daley, Enriquez, Gottlieb, Kahn, Klausner, Tavazoie, Fabi, Offodile II, Sherkow, Sullenger, Freiling, and Balatbat. 2023. Regenerative Medicine: Case Study for Understanding and Anticipating Emerging Science and Technology. NAM Perspectives. Discussion Paper, National Academy of Medicine, Washington, DC.

Charo, “Unchaining Workers,” in Creating a New Moral Political Economy (special issue, Ugolnick ed.) Daedalus vol. 152, no 1 (January 2023).

Almeida-Porada, **Charo**, David et al, “Prenatal Somatic Cell Gene Therapies: Charting a Path towards Clinical Applications,” Journal of Clinical Pharmacology 62 Suppl 1:S36-S52 (Sept 2022).

Hamburg, Yassif, **Charo** and Severance , “Taking Action to Safeguard Bioscience and Protect Against Future Global Biological Risks,” AAAS Science Diplomacy and Emerging Technologies Special Issue (March 2022) <https://www.sciencediplomacy.org/perspective/2022/taking-action-safeguard-bioscience-and-protect-against-future-global-biological>

Charo, “Genome Editing: Global Governance,” ARRIGE Newsletter (October 2021) Available athttps://www.arrige.org/wp-content/uploads/2021/11/ARRIGE\_newsletter4.pdf

Charo, “Vigilante Injustice — Deputizing and Weaponizing the Public to Stop Abortions” N Engl J Med 2021; 385:1441-1443 (on-line, Sept 22, 2021)

Phelan et al (including **Charo**), **“**Intended Consequences Statement” Conservation Science and Practice Vol 3, Issue 4 (March 2021)

Beyond 2020: A Vision and Pathway for NIH: Recommendations for a Healthier Future” (November 2020) (member of working group led by Keith Yamamoto) https://www.coalitionforlifesciences.org/beyond-2020-a-vision-and-pathway-for-nih/

Charo, “Ruthless Health Law” N Engl J Med 2020; 383:e115 (on-line, Sept 30, 2020)

**Charo**, Barker & Sugarman, “Informed Consent for Stem Cell–Based Interventions—Reply”

JAMA. March 2020;323(9):894

**Charo** and Sugarman, "Esssential Elements of Informed Consent for Stem Cell Therapeutic Interventions" (white paper for the International Society for Stem Cell Research) (2020)

Charo, "Who's Afraid of the Big Bad (Germline Editing) Wolf" Perspectives in Biology and Medicine 63(1):93 (February 2020)

**Charo**, Hughes, Kahn and Zoloth, "Fundamental Principles for Ethical Development of Biotechnology" (white paper for Annenberg Foundation) (2019)

J. Sugarman, Barker **and Charo**, " A Professional Standard for Informed Consent for Stem Cell Therapies

Journal of the American Medical Association November 2019; 322(17):1651-1652.

R. Lehmann, Lee, Shugart, Benedetti, **Charo**, Gartner, Hogan, Knoblich, Nelson, and Wilson, "Human organoids: a new dimension in cell biology" Molecular Biology of the Cell 30(10) (Published Online: 29 Apr 2019 https://doi.org/10.1091/mbc.E19-03-0135)

Charo, "Rogues and Regulation of Germline Editing" New England Journal of Medicine 2019; 380:976-980 (published on line January 16, 2019, in print March 7, 2019).

Charo, "Legal Issues Related to Human Germline Genome Editing in the United States" in Taupitz (ed.), "Rechtliche Aspekte der Genom-Editierung an der menschlichen Keimbahn“ (Springer, 2019).

Rand and Dickerson, rapporteurs (**Charo**, Kahn and King developers and advisors) " Framework for Addressing Ethical Dimensions of Emerging and Innovative Biomedical Technologies: A Synthesis of Relevant National Academies Reports" (2019)

Charo, "Germline Engineering and Human Rights," in Huneeus, ed., "The Universal Declaration of Human Rights and the Future of Being  Human (American Journal of International Law -- "Unbound" Symposium) (December 12, 2018)

Freedman and **Charo**, “When conscience calls for treatment: The challenge of reproductive care in religious hospitals” NAM Perspectives (National Academy of Medicine)

https://nam.edu/when-conscience-callsfor-treatment-the-challenge-of-reproductive-carein-religious hospitals (April 30, 2018).

Charo, “Summary of US Law Governing Germline Gene Editing” for the German Federal Ministry of Education and Research project entitled “GenE-TyPE: A Biomedical, Ethical and Legal analysis of Modern Techniques of Genome Editing and its Potential Application.” (2017)

Charo, "The Trump Administration and the Abandonment of Teen Pregnancy Prevention Programs" Jour. of the American Medical Association - Internal Medicine 2017;177(11):1557-1558. (Aug. 28, 2017)

Charo, “Alternative Science and Human Reproduction” New England Journal of Medicine 2017; 377: 309-311 (July 27, 2017) (on-line June 14, 2017)

**Charo** and Hynes, “Evolving Policy with Science” Science 355(6328):889 (March 3, 2017)

Charo, “Whole Women’s Victory — or Not?” New England Journal of Medicine 2016; 375:809-811 (September 1, 2016)

Charo, “The Legal and Regulatory Context for Human Gene Editing.” Issues in Science and Technology 32(3): 39-45 (Spring 2016)

Charo, “On the Road (to a Cure?)” New England Journal of Medicine 2016; 374:901-903 (March 10, 2016)

Sharfstein and **Charo,** “The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns.” Journal of the American Medical Association (November 2015; 314(17):1795-1796)

Carroll and **Charo**, “The Societal Opportunities and Challenges of Genome Editing.” Genome Biology (November 2015). 16:242-248

**Charo** and Greely, “CRISPR Critters: Legal and Ethical Issues in Non-Human Gene Editing,” American Journal of Bioethics (Vol. 15 No. 12 | December 2015pp 11-17) (December 2015)

Charo, "Speed *versus* Safety in Drug Development" in Cohen and Lynch (eds), Food and Drug Law in the 21st Century (Columbia University Press; September 2015)

Charo, “Fetal Tissue Fallout” New England Journal of Medicine 373:890-891 (Sept 3, 2015)

Charo, “Yellow Light Traffic Signals for Emerging Technologies,” Science 24 July 2015:

Vol. 349 no. 6246 pp. 384-385.

Baltimore, Berg, Botchan, Carroll, **Charo**, Church, Corn, Daley, Doudna, Fenner, Greely, Jinek, Martin, Penhoet, Puck, Sternberg, Weissman, Yamamoto “A prudent path forward for genomic engineering and germline gene modification” Science 3 April 2015: Vol. 348 no. 6230 pp. 36-38.

Charo, “The Supreme Court Decision in the Hobby Lobby Case: Conscience, Complicity, and Contraception.” Journal of the American Medical Association: Intern Med. 2014;174(10):1537-1538.

Charo, “Physicians and the (Woman’s) Body Politic,” N Engl J Med 2014; 370:193-195 (January 16, 2014)

Charo, "The Complexity of Integrating Speed and Safety in Drug Development, " JAMA Internal Medicine 2013;():1-2. (April 8, 2013)

Charo, "Warning: Contraceptive Drugs May Cause Political Headaches," N Engl J Med 2012; 366:1361-1364 (April 12, 2012)

Charo, “Politics and Bioethics,” in Moreno (ed.), Progressive Bioethics (Johns Hopkins Univ. Press, 2009)

Rosenfield A, **Charo** R.A. & Chavkin, W., “Moving Forward on Reproductive Health,” 359(18) New England Journal of Medicine 1869-1871 (2008).

Chavkin W, Rosenbaum S., **Charo RA**. "Women's health and health care reform: the key role of comprehensive reproductive health care: a white paper." New York: Mailman School of Public Health, Columbia University, 2008. (<http://www.mailmanschool.org/facultypubs/womenshealthcarereform.pdf>)

Liao, Goldschmidt, Sugarman, Bok, Brown, **Charo**, Faden, Hare, Kahn, Kurtzberg, Manton, Moreno, Shanwani, Sulmasy, Taylor, Zoloth, “Ethical and Policy Issues Related to Progenitor Cell-Based Strategies for Prevention of Atherosclerosis,” 33 Journal of Medical Ethics 643-646 (2007)

Charo, “The Endarkenment,” in Lisa Eckenwiler and Felicia Cohn (eds), The Ethics of Bioethics: Mapping the Moral Landscape (Johns Hopkins University Press, June 2007)

Charo, “Politics, Parents, and Prophylaxis — Mandating HPV Vaccination in the United States” 356(21) New England Journal of Medicine 1905-1908 (May 10, 2007).

Charo, “The Partial Death of Abortion Rights” 356(21) New England Journal of Medicine 2125-2128 (May 24, 2007).

Psaty and **Charo**, “FDA Responds to Institute of Medicine Drug Safety Recommendations—In Part”

297 Journal of the American Medical Association 1917 – 1920 (May 2, 2007).

Charo, “Health Care Provider Refusals to Treat, Prescribe, Refer or Inform: Professionalism and Conscience,” American Constitution Society, White Paper Series, <http://www.acslaw.org/node/4214> (February 8, 2007)

Daley, Ahrlund-Richter, Auerbach,, Benvenisty, **Charo**, Chen, Deng, Goldstein, Hudson, Hyun, Junn, Love, Lee, McLaren, Mummery, Nakatsuji, Racowsky, Rooke, Rossant, Scholer, Solbakk, Taylor, Trounson, Weissman, Wilmut, Yu, Zoloth, “The ISSCR guidelines for human embryonic stem cell research,” 315(5812) Science 603-604 (February 2, 2007)

Charo, “Body of Research – Ownership of Human Tissue,” 355(15) New England Journal of Medicine 1517-1519 (October 12, 2006)

Charo, “Fear and the First Amendment and Scientific Freedom,” 36(5) The Hastings Center Report 12-13 (September/October 2006)

Charo, “Realbioethik,” 35(4) The Hastings Center Report 13-14 (July/August 2005)

Charo, “The Celestial Fire of Conscience: Physicians, Pharmacists and Conscience Clauses,” 352(24) New England Journal of Medicine 2741-2743 (June 16, 2005)

Charo, “Ethical Issues in Embryo Research,” in Odorico, Pedreson and Zhang (eds.), Human Embryonic Stem Cells (BIOS Scientific Publishers, 2004)

Charo, “Research Uses of Human Biological Materials,” in Lazar (ed.), DNA and the Criminal Justice System (Oxford, 2004)

Charo, “Passing on the Right: Conservative Bioethics is Closer Than It Appears” 32(2) Journal of Law, Medicine and Ethics 307 - 320 (2004)

Charo, “The Promethean Fire of Cloning: A Review of Klotzko, A Clone of Your Own,” 6 Nature/Cell Biology 377 (2004)

Charo, “Legal Characterizations of Human Tissue,” in Youngner, Anderson and Schapiro (eds.), Transplanting Human Tissue: Ethics, Policy and Practice (2004, Oxford University Press)

Charo, “Review of Maienschein, Whose View of Life? Embryos, Cloning and Stem Cells,” 350(15) New England Journal of Medicine 1583-1584 (2004)

Charo, “Cloning Debates: A Review of Bonnicksen, Crafting a Cloning Policy,” 32 Nature/Genetics 567 (2002)

Charo, “Children by choice: reproductive technologies and the boundaries of personal autonomy,” 4 (S1) Nature/Cell Biology S23–S29 (2002) and 8 (S1) Nature/Medicine S23–S29 (2002)

Charo, “Wars of Petition,” Hastings Center Report (May/June 2002)

Charo, “Skin and Bones: Markets and Human Biological Materials,” 26(2) Nova Law Review 421-451 (winter 2002)

Charo, “The Ethics of Control, (2)1 Yale Journal of Health Law and Policy 102-111 (Winter 2002)

Charo, "Bush's Stem Cell Compromise: A Few Mirrors?" 31(6) Hastings Center Report 6 (December 2001)

Charo, “Principe de precaution, bioethique, et role des conseils publics d’ethique” [“The Precautionary Principle, Bioethics, and the Role of Public Ethics Commissions”], in Les Cahiers du Comite Consultatif National d’Ethique pour les Sciences de la Vie et de la Sante 27-29 (Paris, 2000)

Charo, “Patents, Licenses, and Antitrust Violations in the Development and Deployment of Genetic Test Kits” (30 pp). For the National Science Foundation, grant to study ethical issues raised by the marketing of genetic tests, Professor Allan Buchanan, Principal Investigator (1999).

Charo, “Genethics and Genlaw for Medical Students” (40 pp). For the Josiah Macy Jr. Foundation Conference on Integrating Genetics into the Medical Curriculum (1998).

Charo, “Les effets de la politique de l’avortement sur les services diagnostique preimplantatoires,” [”The Effect of Abortion Politics on Preimplantation Diagnostic Services”] in Proceedings of the International Meeting on Preimplantation Diagnosis (1998)

Charo, “Every Cell is Sacred: The Impact of Cloning on the Argument from Potential,” in P. Lauritzen (ed.), Cloning and the Future of Embryo Research (Oxford University Press, 2000)

Charo, Review of J. Shroedel, Is the Fetus a Person? A Comparison of Policies Across Fifty States, 343(23) New England Journal of Medicine (December 7, 2000)

Charo, “Cloning, Ethics, and Public Policy,” 27 Hofstra Law Review 503-508 (Spring 1999) (reprinted in Mackinnon (ed.), Cloning (University of Illinois Press 2000)

Charo, "From Dusk to Dawn: The Use of Biological Categories for Ordering Legal Rights," in Youngner, Arnold, and Schapiro (eds.), The Definition of Death: Contemporary Controversies (Johns Hopkins Univ. Press; 1999)

Charo, “The Stuart Rome Lecture: Biological Truths and Legal Fictions,” 1(2) Journal of Health Care Law and Policy 701-727 (1998)

Charo, “Dealing with Dolly: Cloning and the National Bioethics Advisory Commission” 38(1) Jurimetrics 11-22 (Fall 1997)

Charo, “Update on the National Bioethics Advisory Commission,” Protecting Human Subjects 10-11 (Office of Biological and Environmental Research, U.S. Department of Energy, Fall 1997)

Charo, “The National Bioethics Advisory Commission: Bridging the Tension Between Scientific and Public Policy Analysis,” 1(2) Biolaw and Business 86-91 (1997)

Charo, “Abortion Politics v. Science,” The Capital Times at p. 12A (Sept. 19, 1997)

Andrews, **Charo**, Garfinkle, Latham, Podgers & Rothstein, “The Clone Age,” 83 American Bar Association Journal 68-72 (July 1997)

Charo, "Family Planning Policies and the Politics of New Reproductive Technologies," in K. Petersen (ed.), Intersections: Women on Law, Medicine and Technology (Dartmouth Publishing, 1997)

Charo, Review of Anne Hellum (ed.), Birth Law, 4 NORA 67-69 (1996)

Charo, "Principles and Pragmatism," 6 Kennedy Institute of Ethics Journal 319-322 (1996)

Charo, "Embryo Research: An Argument for Federal Funding," 4(6) J. of Women's Health 603-608 (1995)

Charo, "The Hunting of the Snark: The Moral Status of Embryos, Right-to-Lifers, and Third World Women," 6(2) Stanford Law and Policy Review 1-38 (1995)

Charo, Review of Rebecca Cook, Women's Health and Human Rights in 23(2) Journal of Law, Medicine & Ethics 195-198 (1995)

Charo, "Le Penible Valse Hesitation: Fetal Tissue Research Review, and the Use of Bioethics Commissions in France and the United States," In R. Bulger, et al, eds., Society's Choices: Social and Ethical Decision Making in Biomedicine 477-500 (National Academy Press, 1995)

Charo, "Reproductive Technologies: Legal and Regulatory Issues," in Encyclopedia of Bioethics 2241-2248 (Simon & Schuster 1995)

Charo, "A Brief Overview of Constitutional Issues Raised by Excluding Women from Research Protocols" in Anna Mastroianni, Ruth Faden, and Daniel Federman (eds.), Women and Health Research: Ethical and legal Issues of Including Women in Clinical Studies (vol. II, Workshop and Commissioned Papers) 84-90 (Institute of Medicine, National Academy Press, 1994)

Charo, "And Baby Makes Three," in Mark S. Frankel and Albert H. Teich (eds.), The Genetic Frontier: Ethics, Law, and Policy 25-44 (American Association for the Advancement of Science, 1994)

Rothenberg & **Charo**, "The Good Mother: The Limits of Reproductive Responsibility and Genetic Choice," in Karen Rothenberg and Elizabeth Thomson (eds), Women & Prenatal Testing: Facing the Challenges of Genetic Technology 105-130 (Ohio St. Univ Press, 1994)

Charo, "Biological Determinism in Legal Decisionmaking: The Parent Trap" 3 Texas Journal of Women and the Law 265-307 (1994)

Charo, "The Human Genome Initiative, Women's Rights and Reproductive Decisions," 1994(4) Reproductive Health Matters 80-88 (Nov. 1994)

Charo, “The Civil Rights Struggle Over Human Reproduction: A Review of David Garrow, Liberty and Sexuality: The Right to Privacy and the Making of Roe v. Wade, in 26(4) Family Planning Perspectives 181-182 (July/August 1994)

Charo, Review of Cynthia Daniels, At Women's Expense: State Power and the Politics of Fetal Rights, in 330(9) New England Journal of Medicine (March 3, 1994)

Charo, "And Baby Makes Three - Or Four, Or Five, Or Six: Redefining the Family After the Reprotech Revolution" 8 Wisconsin Women's Law Journal 1-29 (1992-1993)

Charo, Review of conference "Antiprogestins and the Law," in 44(4) International Digest of Health Legislation 348-350 (1993)

Charo, "Protecting Us to Death: Women, Pregnancy, and Clinical Research Trials," 38(1) St. Louis University Law Journal 135-187 (1993)

Charo, "The Effect of the Human Genome Initiative on Women's Reproductive Decisionmaking," in 8 (Supp. 1) Fetal Diagnosis and Therapy 148-159 (1993)

Charo, “Medical Issues and Questions of Medical Policy in the Abortion Debate in Germany,” Proceedings of the American Institute for Contemporary German Studies Humanities Workshops (1993)

Charo, "Legal and Regulatory Issues Surrounding Carrier Testing, 36(3) Clinical Obstetrics and Gynecology 568-597 (1993)

Charo, "The Interaction Between Family Planning Policy and the Development of New Reproductive Technologies," 11(2) Law in Context 58-81 (1993), reprinted in K. Peterson (ed.), Intersections: Women on Law, Medicine & Technology (Ashgate/Dartmouth Press, Sydney, 1997)

Charo, "Life After Casey: The View from Rehnquist's Potemkin Village," 21(1) Journal of Law, Medicine & Ethics 59-66 (1993)

Charo, "Legal Issues in Population Screening for CF Trait: Standards of Care in Genetic Counseling, Insurance Risk Classification, and Regulation of Laboratories and Genetic Test Kits" (75 pp). For congressional Office of Technology Assessment (1992).

Charo, "Mommies Dearest," 1992 University of Wisconsin Law Review 233-37 (1992)

Charo, Review of Athena Liu, Artificial Reproduction and the Law in International Digest of Health Legislation 170-172 (1992)

Charo, "Cippolone Cigarette Case Dismissed," 340 Lancet 1283 (11/21/92)

Charo, "Prospects for Cystic Fibrosis Carrier Screening" 340 Lancet 478 (8/22/92)

Charo, “New York Surrogacy Law,” 340 Lancet 361 (8/8/92)

Charo, "Personal Importation of Mifepristone," 340 Lancet 229 (7/25/92)

Charo, "The Undue Burden of Abortion," 340 Lancet 44 (7/4/92)

Charo, "Mandatory Contraception," 339 Lancet 1104-05 (5/2/92)

Charo, "RU-486" in Barbara Katz Rothman (ed.), Encyclopedia of Childbearing (Oryx Press, 1992)

Charo, "United States: Surrogacy", in Sheila A.M. McLean (ed.), Law Reform and Human Reproduction (Dartmouth Publishing, Hampshire, U.K., 1992)

Charo, Review of Robert Blank, Regulating Reproduction, ll(l) Journal of Politics and the Life Sciences 115-119 (1992)

Charo, "A Political History of RU-486", in Kathi E. Hanna (ed.), Biomedical Politics 43-88 (Institute of Medicine, National Academy Press, 1991)

Charo, Review of "1990 ASLM Annual Health Law Teachers Conference," 42 International Digest of Health Legislation 170-172 (1991)

Charo, Review of "St. Louis University Symposium on Rationing Health Care for the Elderly," 41 International Digest of Health Legislation 752-754 (1991)

Charo, Review of 'Mouvement des Femmes Québecoises, Sortir la Maternité du Laboratoire' in 41 International Digest of Health Legislation 365-370 (1990)

Charo, “Reproductive Rights and Wrongs: A Review of Nadine Taub et al Reproductive Laws for the 1990s, in 22(1) Family Planning Perspectives 47-48 (1990)

Charo, Review of N.Y.S. Task Force Report on Surrogacy, in 10 Journal of Legal Medicine 251 (1989)

Charo, "Bioethics in the U.S.: Looking Back & Looking Ahead," in Byk (ed.), 'Procréation Artificielle: Ou En Sont le Droit? Une Contribution Multidisciplinaire et Internationale' 249-259 (Editions Alexandre Lacassagne, 1989)

Charo, "Legislative Approaches to Surrogate Motherhood," 16(1-2) Journal of Law, Medicine and Health Care 96-112 (Spring/Summer 1988), reprinted in Larry Gostin (ed.), Surrogate Motherhood: Politics and Privacy (Indiana University Press, 1990)

Goodwin, McGreevey & **Charo**, “Options for Population Planning: Midterm Evaluation” (International Science & Technology Institute Report 89-048-099) (August 1990)

Charo, "Evaluation of Legal and Regulatory Obstacles to Expanding Public and Private Sector Family Planning Services in Ghana" (65 pp) (based on 30-day research trip to Accra). For US Agency for International Development (1990).

Charo, "Congressional Options for Action with Regard to Genetic Testing in the Workplace" (25 pp). For congressional Office of Technology Assessment (1989).

Charo, "Evaluation of Draft State Legislation on Living Wills and Advanced Directives." Submitted to N.J. Bioethics Commission (1988).

Charo, "Commercializing Surrogate Motherhood," in Elaine Hoffman Baruch and Amadeo D'Adamo (ed.), Embryos, Ethics, and Women's Rights (Harrington Park Press, 1988)

Charo, "Problems in Commercialized Surrogate Mothering," 13 (1-2) Women's Health 195-201 (1987)

Einhorn & **Charo** "Carbon Dioxide and the Greenhouse Effect: Possibilities for Legislative Action," 11 Columbia Journal of Environmental Law 495-516 (1986)

**Charo**, Stearns, & Mallory, "Alternative Energy Power Production: The Impact of the Public Utility Regulatory Policy Act," 11 Columbia Journal of Environmental Law 447-494 (1986)

Sampson & **Charo**, "Access to Sunlight: Resolving Legal Issues to Encourage the Use of Solar Energy," 11 Columbia Journal of Environmental Law 417-445 (1986)

Mallory & **Charo**, "Federal and State Mandatory Beverage Container Deposit Legislation," 11 Columbia Journal of Environmental Law 355-378 (1986)

**Charo**, Stearns, & Case, "Overview of Legal Issues Arising in the Development of Federal and State Appliance Efficiency Standards," 11 Columbia Journal of Environmental Law 315-353 (1986)

Charo, "Designing Mathematical Models to Describe One-Person, One-Vote Compliance by Unique Governmental Structures: The Case of the New York City Board of Estimate," 53 Fordham Law Review 735-811 (1985)

Grad & **Charo,** "The N.Y.S. Tax Appeals System: Evaluation and Possible Changes," (65 pp) a report to the NYS Select Committee on Tax Reform (1983).

Charo, "Class Actions and Mass Toxic Torts," 8 Columbia Journal of Environmental Law 269-307 (1982)

Charo, "A Specific Proposal for Hybrid Rulemaking," 7 Columbia Journal of Environmental Law 69-97 (1981)

**NEWSPAPER AND MAGAZINE ARTICLES**

Charo, “The Rationing of Care May Lead to Lawsuits Against Doctors. Here Is What We Should Do to Protect Them” Newsweek Magazine (April 6, 2020)

Charo, “Viewpoint: Why I Believe Fetal Tissue Research Is Pro-Life.” AAMC Reporter: November 2015

Charo, “Yes, Republicans are outraged about Planned Parenthood. But they used to support fetal tissue research.” Washington Post, August 6, 2015.

Charo, “A Proposal for Mom’s to Be,” Washington Post (Outlook Section) (May 24, 2013)

Charo and Zoloth, “Stem Cell Research: Issue for Women, Los Angeles Times at p. 11 (August 12, 2002)

Backlar, **Charo** et al, “Don’t Throw the Bath Water Out with the Baby,” Reason (October 26, 2001)

Charo, “Bush’s Stem Cell Decision” Chronicle of Higher Education (September 7, 2001)

Charo, “Playing God? Or Playing Human,” Washington Post (Outlook Section, p. B01, August 12, 2001)

Charo, “Academe Should Support New Guidelines to Protect Mentally Ill Research Subjects,” 45(29) The Chronicle of Higher Education B9-10 (March 26, 1999)

Charo, Review of Renate Duelli Klein et al, 'RU486: Myths, Morals, & Misconceptions' and Baulieu, 'The Abortion Pil'l IX(9) The Women's Review of Books:18-19 (June 1992)

**UNIVERSITY ACTIVITIES** *(those with administrative or budgetary responsibilities marked with an \*)*

12 - 13 Member, UW-Madison Chancellor Search Committee

10 - 11 Member, Law School Dean Search Committee

07 - 11 \*Member, Executive Committee, UW Stem Cell Center

06 - 09 \*Member, Executive Committee, UW Masters in Biotechnology Program

04 - 05 Member, Faculty Advisory Comm. to Create UW Masters in Public Health

03 - 09 Member, Faculty Advisory Comm., UW Stem Cell Research Program

02 - 09 Member, Scientific Advisory Board, WiCell

02 - 06 Member, Faculty Advisory Committee, MS in Biotechnology Studies

01 - 02 Member, Steering Committee to Create UW Masters in Biotechnology Studies

00 - 01 \*Member, University Committee (executive committee of the Faculty Senate)

00 - 01 Member, UW Admissions Committee Oversight Board

00 - 01 Member, UW Provost Search and Screen Committee

98 - 05 Member, U.W. University Bioethics Advisory Committee

98 - 99 Member, UW Law School Self-Study Comm. For ABA Re-accreditation

97 - 00 \*Member (Chair, 99-00), Committee on Faculty Rights and Responsibilities

89 - 91, 95 - 04 Member, Human Subjects Committee (“IRB”), Center for Health Sciences

92 - 94 Member, All-Campus Committee (oversight of human subjects' protections)

89 - 95 Faculty Advisor, Wisconsin Health Law Association

89, 90, 93 Member, Univ. of Wisconsin Biotechnology Center Faculty Advisory Comm.

89-91, 93-95 University of Wisconsin Hospital Ethics Committee